3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
1
Gallbladder Neoplasms
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
18
Cisplatin
12
Oxaliplatin
7
pembrolizumab
6
Nivolumab
6
Capecitabine
4
trametinib
3
Fluorouracil
3
Bevacizumab
3
tremelimumab
2
lenvatinib
2
durvalumab
2
derazantinib
2
atezolizumab
2
Trastuzumab
2
Ramucirumab
2
Radiofrequency Ablation
2
Panitumumab
2
Leucovorin
2
Cryosurgery
2
zanidatamab
1
vandetanib
1
tucatinib
1
tocilizumab
1
telotristat ethyl
1
sargramostim
1
rucaparib
1
regorafenib
1
pertuzumab
1
milademetan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Biliary Tract Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts